Application closing date 02/01/2020 Salary 33,797 - 40,322 per annum Job category/type ResearchAttachments

Job description

Queen's University Belfast is a driver of innovation based on our talented, multinational workforce. Throughout the University, our academics are collaborating across disciplines to develop new discoveries and insights, working with outside agencies and institutions on projects of international significance. We are connected and networked withstrategic partnerships across the world, helping us to expand our impact on wider society locally, nationally and globally. The University is committed to attracting, retaining and developing the best global talent within an environment that enables them to realise their full potential.

We are a leader in gender equality and diversity, and are one of the UK's most successful universities in the Athena SWAN initiative which promotes gender equality and career progression. The School of MDBS holds an Athena SWAN Silver award in recognition of our commitment and success in addressing gender equality, representation, progression and success for all our staff. We are ranked 1st in the UK for knowledge transfer partnerships, (Innovate UK) 9th in the UK for University facilities (Times Higher Education Student Experience Survey 2018) and 14th in the UK for research quality (Times and Sunday Times Good University Guide 2019).

Based in Belfast, a modern capital city, our beautiful campus is surrounded by abundant acres of parkland and is renowned as one of the safest and affordable cities in the UK. The choice of local Schools from pre-nursery upwards are some of the best available, and lovers of the outdoors can enjoy any number of activities from rowing and kayaking to top class golf among many others. We are immensely proud of what our city and our University will offer you.

Our five core values - Integrity, Connected, Ambition, Respect, Excellence - are shared by our staff and students, representing the expectations we have for ourselves and each other, guiding our day-to-day decisions and the way we behave as individuals in an international organisation.

The Wellcome Wolfson Institute for Experimental Medicine (WWIEM) is an interdisciplinary research centre which is committed to the highest quality scientific endeavour, with over 250 basic and clinical scientists working on site.Our mission is to understand the mechanisms of disease and use that understanding to develop innovative new treatments and therapies to improve patient outcomes.

We are recruiting for a Research Fellow to join the Vascular Stem Cell Biology Research team within the WWIEM led by Prof Alan Stitt to work on a project funded by the British Heart Foundation (BHF). The project will employ in in vitro and in vivo model systems and cell and molecular biological approaches to investigate the regulation of metabolism in vascular progenitors to improve tissue regeneration in ischaemic disease. The successful candidate will design, develop and refine experimental models to investigate vascular repair and re-perfusion of ischaemic tissues in order to obtain reliable and reproducible data.

The successful candidate must:

Candidate Information

Informal enquiries may be directed to Dr Christina O'Neilll via email:christina.oneill@qub.ac.uk

About the GroupFurther Information about the InstituteFurther Information for International ApplicantsNote to EAA Applicants on Brexit

The rest is here:
Research Fellow in Vascular Stem Cell Biology job with QUEENS UNIVERSITY BELFAST | 190420 - Times Higher Education (THE)

DUBLIN--(BUSINESS WIRE)--The "Synthetic Biology: Global Markets" report has been added to ResearchAndMarkets.com's offering.

The study scope includes core synthetic biology products (e.g., oligonucleotides, synthetic genes, BioBrick parts, delivery plasmids, chassis organisms, synthetic cells, cell-based and cell-free production systems), enabling technologies (e.g., DNA sequencing, DNA synthesis, gene editing, bioinformatics, specialty media) and enabled technologies (e.g., healthcare, industrial chemicals, consumer products, food and beverage, agriculture) that are already commercialized or are forecast to be commercialized through 2024.

Key synthetic biology technologies and products are analyzed to determine present and future market status, as well as forecasted growth from 2019 to 2024. In-depth discussion of strategic alliances, industry structures, competitive dynamics, patents and market driving forces is also provided.

The author examines the synthetic biology industry by market segment, including DNA sequencing, DNA synthesis, gene editing, synthetic biology foundries and software; as well as the agriculture; consumer products, cosmetics and skin care, food and beverage, healthcare and industrial chemicals enable product sectors.

The role of key strategic alliances and acquisitions from January 2018 to September 2019 is discussed. Emerging markets, including synthetic genes, synthetic-biology-enabled drugs and vaccines, genome-edited crops and chassis organisms; as well as metabolically engineered factories for producing synthetic fuels and specialty chemicals, are analyzed, and more than 215 companies in these fields are highlighted.

The report includes:

Market Insights

The synthetic biology industry is a prime growth opportunity due to several factors. First, many of the applications for synthetic biology have large addressable markets and the penetration rate is still modest; the industry will experience explosive growth as these penetration rates accelerate. Second, development of exciting new technologies is driving innovation within the industry. These technologies include ultra-high-throughput screening platforms for organism design, enzymatic DNA synthesis and novel gene editing platforms. Third, the industry is focusing on value-added products, placing less emphasis on cost-sensitive, commodity products.

Synthetic biology foundries now routinely design, build and test designer organisms capable of producing valuable end products. The workflow includes modifying the genomes of these organisms to produce just the right combination of taste and texture, as for the food industry. Designer organisms in the textile industry help achieve the right combination of strength, flexibility, weight, dimensional variability, and targeted surface and structural modification. High-value synthetic biology end products such as these are forecast to drive significant market growth in this industry.

This report provides in-depth coverage of the dynamic synthetic biology industry, including insights into its component technologies and market segments, as well as its leading participants.

The synthetic biology industry consists of three main sets of technologies and products: enabling, core and enabled. Enabling technologies and products are the engines that drive the development of the synthetic biology industry. Core products and technologies, including standardized DNA parts, synthetic genes and chassis organisms, are the key tools by which cellular factories and systems produce enabled products.

Synthetic biology-enabled products (e.g., pharmaceuticals, chemicals, biofuels, agricultural, textiles, food) have large downstream market potential. Synthetic biology technologies add value in each of these downstream industries. In agriculture, synthetic biology makes it possible to produce crops with desired traits, such as pest resistance or high yields. Synthetic biology allows for the production of foods free of animal products, meeting an emerging consumer need in this industry.

Key Topics Covered

1. Introduction

2. Summary and Highlights

3. Overview

4. Technology Background

5. Synthetic Biology Applications

6. Synthetic Biology Industry

7. Synthetic Biology Markets

8. Patents

9. Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/9vvv4h

See more here:
Synthetic Biology Industry Outlook to 2024 Featuring Leading Players Active Motif, Bayer, BASF, Cargill, DowDuPont, GlaxoSmithKline, Merck, Novartis...

For all of the wondrous potential of immunotherapies, there have been some notable obstacles in the early goings. Engineering immune cells to attack cancerous tumors can lead to solid results shortly after administering a dose, but for many patients the effects wear off once rapidly mutating tumor cells acquire new defense mechanisms.

Cellectis (NASDAQ:CLLS) thinks it may have a partial solution. In mid-November, the gene editing company published the results from a proof of concept study for its "smart" immunotherapy approach. Is the technique the future of cellular medicine?

Image source: Getty Images.

Today, cellular oncology therapies genetically engineer immune cells to bolster their safety and efficacy as a cancer treatment. There are T cells, natural killer (NK) cells, tumor infiltrating lymphocytes (TILs), and others. They're often engineered with chimeric antigen receptors (CARs) or T cell receptors (TCRs), which allow them to home in on and suppress specific genes in cancer cells.

While current-generation CAR T cells or CAR NK cells are capable of mounting formidable attacks on tumors at first, treatment responses aren't durable for all patients. That's because cancer cells mutate to rely on different proliferation genes, or secrete new molecules into the tumor microenvironment that neutralize immune cells. Meanwhile, overstimulating the immune system can reduce the potency of immune cells and lead to devastating side effects, such as cytokine release syndrome.

That prompted Cellectis to design "smart" CAR T cells capable of adapting to changes in the tumor microenvironment. In a proof of concept study, the company utilized synthetic biology concepts to rewire genetic circuits in three different genes of the initial T cells.

One edit made the immunotherapy more potent, but in a controlled manner to reduce off-target toxicity. The other two edits imbued CAR T cells with the ability to secrete inflammatory proteins inside the tumor microenvironment in proportion to the concentration of cancer cells.

In other words, the smart CAR T cells only asked for help from the rest of the immune system when it was needed most, which increased the anti-tumor activity of treatment and made native immune cells less likely to become neutralized. That should reduce the likelihood of triggering cytokine release syndrome, the most common (and potentially fatal) side effect of cellular medicines, which is caused by high concentrations of immune cells.

The study was conducted in mice, which means the safety and efficacy observations can't be extrapolated into humans. But that wasn't the point. The proof of concept demonstrates that the basic idea of engineering tightly controlled genetic circuits into immunotherapies is feasible. It could even allow multiple genetic circuits of the same drug candidate to be tested against one another in parallel, hastening drug development and lowering costs. Is it the inevitable future of cellular medicine?

Image source: Getty Images.

Gene editing tools are required to engineer immune cells. In fact, immunotherapies are the lowest hanging fruit for gene editing technology platforms today. It's simply easier to engineer immune cells in the lab (ex vivo) than it is to engineer specific cell types in the complex environment of the human body (in vivo).

That explains why nearly every leading gene editing company has immunotherapy programs in its pipeline. Coincidentally, all of the leading drug candidates in the industry pipeline are off-the-shelf CAR T cells engineered to treat CD19 malignancies such as non-Hodgkin's lymphoma (NHL) and B-acute lymphoblastic leukemia (B-ALL), regardless of the gene editing approach used. The smart CAR T cells designed by Cellectis targeted CD22 malignancies, but the approach could be adapted to CD19 antigen.

Developer(s)

Drug Candidate

Gene Editing Approach

Development Status

Cellectis and Servier

UCART19

TALEN

Phase 2

Precision BioSciences (NASDAQ:DTIL)

PCAR0191

ARCUS gene editing

Phase 1/2

CRISPR Therapeutics (NASDAQ:CRSP)

CTX110

CRISPR-Cas9

Phase 1/2

Sangamo Therapeutics (NASDAQ:SGMO) and Gilead Sciences (NASDAQ:GILD)

KITE-037

Zinc finger nuclease

Preclinical

Data source: Company websites.

Will these companies eventually turn to "smart" immunotherapies with regulated genetic circuits? It does seem inevitable, especially if the approach can reduce or eliminate cytokine release syndrome and enable more durable responses.

For example, Cellectis reported that all seven patients taking part in the phase 1 trial of UCART19 suffered from at least grade 1 cytokine release syndrome, which caused complications that led to the death of one patient. Five of the seven patients achieved molecular remission, but one relapsed (and remained alive) and one died. To be fair, all patients taking part in the trial had advanced, heavily pretreated B-ALL.

Precision BioSciences has encountered similar obstacles in an ongoing phase 1/2 trial of PBCAR0191. The company's lead drug candidate was administered to nine patients with NHL or B-ALL. Three cases of cytokine release syndrome were reported, but all were manageable. Seven responded to treatment, including two that achieved a complete response, but three eventually relapsed.

CRISPR Therapeutics recently began dosing patients with CTX110 in a phase 1/2 trial that will eventually enroll up to 95 individuals, but initial results won't be available until 2020. Sangamo Therapeutics and Kite Pharma, a subsidiary of Gilead Sciences, are plowing ahead with zinc fingers,but are still in preclinical development.

Investors seem pleased with most of these gene editing stocksright now. After all, despite the obstacles, current-generation cellular medicines are delivering impressive results in patient populations with relatively few options. But upcoming data readouts could easily differentiate the pack. That could increase the need to invest in augmented capabilities, such as smart immunotherapies.

There's plenty of untapped potential in cellular medicine. Today, companies are developing drug candidates with engineered CARs and TCRs designed to test hypotheses about the function of immunotherapies. As approaches find success, measured in safer and more durable responses, the next layer of complexity will be added in an effort to find even more successful therapies. And the cycle will continue.

Therefore, it seems inevitable that the field of cellular medicine will turn to smart immunotherapies with more complex genetic edits, much like the field quickly embraced the need for engineered immune cells and off-the-shelf manufacturing processes. That said, the immediate focus for Cellectis and its peers is building a stable foundation -- and those efforts have only just begun.

View post:
Did Cellectis Just Provide a Glimpse of the Future of Cellular Medicine? - The Motley Fool

Transparency Market Research has published a new report on the biological imaging reagents market for the forecast period of20192027. According to the report, the globalbiological imaging reagents marketwas valued at ~US$ 13.5 Bnin2018and is projected to expand at a CAGR of8.5%from2019to2027.

Global Biological Imaging Reagents Market:Overview

Biological imaging reagents are substances used in research and diagnosis purposes in imaging modalities, to enhance THE visualization of internal organs and in vivo live cell imaging. These reagents are used in different imaging modalities such as X-ray, MRI, and ultrasound for THE diagnosis of different diseases, as well as in drug discovery.

Growth of the global biological imaging reagents market can be attributed to the rise in the demand for diagnostic imaging procedures across the globe. Asia Pacific is a highly lucrative market for biological imaging reagents, due to the improving healthcare infrastructure and increase in the geriatric population. North America dominated the global biological imaging reagents market in2018,and the trend is projected to continue during the forecast period, due to the higher prevalence of diseases and high number of imaging procedures.

Request Sample of Biological Imaging Reagents Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=48474

High Prevalence and Increase in Incidence Rate of Chronic Diseases to Drive Market

The prevalence of chronic diseases has increased in the past few years across the globe. These diseases include cardiovascular diseases, cancer, diabetes, and neurological disorders.

These diseases need diagnostic imaging tests. Life science reagents such as biological imaging reagents are an integral part of a large number of diagnostic imaging tests. Hence, the high prevalence of these chronic diseases and increasing research activities to discover treatments for these diseases are propelling the global biological imaging reagents market. According to WHO, cardiovascular diseases account for around17.9 milliondeaths globally every year, which constitutes an estimated31%of all deaths.

Rise in the number of diagnostic imaging procedures and increase in research activities for new drug development are the other factors driving the global market. Moreover, the launch of new imaging reagents and approval of products for specific indications in the past few years contributed to the growth of the global biological imaging reagents market.

Nuclear Reagents to be Lucrative Option

Based on class, the global biological imaging reagents market has been classified into contrast reagents, optical reagents, and nuclear reagents. The optical reagents segment dominated the global biological imaging reagents market in2018. However, the contrast reagents segment is anticipated to dominate the global market from2019to2027.

Nuclear reagents are expected to be a highly lucrative segment during the forecast period, owing to the better visualization effects of imaging achieved by these reagents and rise in the demand for radiopharmaceutical agents in imaging modalities

Optical Imaging Dominated Global Market

In terms of modality, the global biological imaging reagents market has been categorized into MRI, ultrasound, X-ray & CT, nuclear, optical imaging, and others. The nuclear segment has been bifurcated into PET and SPECT. The optical imaging segment dominated the global biological imaging reagents market in2018, owing to advanced technologies in optical imaging and large number of research activities on this method.

In-vivo to be Promising Application

Based on application, the global biological imaging reagents market has been bifurcated into in vitro and in vivo.The in vitro segment has been classified into proteomics, genomics, and cell biology. In vivo is likely to be a highly promising segment in the next few years, owing to an increase in vivo research activities by CROs for drug discovery, and growth of the biopharmaceutical industry.

Request for a Discount on Biological Imaging Reagents Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=48474

Life Science Companies to be Lucrative End Users

In terms of end user, the global biological imaging reagents market has been divided into diagnostic laboratories, imaging centers, life sciences companies, academic & research institutes, and others. Life science companies are projected to be a highly lucrative segment during the forecast period. The segment is anticipated to expand at a high CAGR from2019to2027. Increase in the research on new drugs & molecules and large number of collaborations between pharmaceutical companies and CROs are the major factors fueling the growth of the life science companies segment.

Competitive Landscape

Bayer AG, Thermo Fisher Scientific, Inc., PerkinElmer, Inc., and Guerbet are the leading players in the global biological imaging reagents market.

The global biological imaging reagents market is fragmented in terms of number of players. Key players in the global market includeBayer AG, Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Guerbet, Lantheus Holdings, Inc., Bracco S.p.A., GE Healthcare, Becton, Dickinson and Company, Siemens Healthineers, and Luminex Corporation.

Here is the original post:
Biological Imaging Reagents Market is Expected to Create New Opportunities By 2027 - Market Research Sheets

Global Incubator Market is created to provide the market landscape and unlimited guidelines about contemporary market size, share, driving factors, trends, progressive growth, and dominant players of the Incubator Market. The report serves overall information on the market to top manufacturers, distributors, traders, dealers. It will help them understand the product scope, market overview, market driving force, technological advancement, market risk, opportunities, and research findings.

The Incubator market was valued at 950 Million US$ in 2018 and is projected to reach 1350 Million US$ by 2025, at a CAGR of 5.1% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Incubator.

Get Sample Copy of this Report

http://www.qymarketresearchstore.com/reports/57443/inquiry/?Mode=86

Key Companies Analyzed in this Report is:

Thermo Fisher Scientific, BINDER GmbH, VWR International, Sheldon Manufacturing, Panasonic, Andreas Hettich GmbH, Memmert, Weiss Technik, Heal Force Bio-meditech Holdings Limited, NuAire, JEIO TECH, Manish Scientific Instruments Company, Genlab Limited, Gemmy Industrial Corp, Shanghai Yiheng, LTE Scientific Ltd.

The leading players of Incubator industry, their market share, product portfolio, company profiles are covered in this report. The competitive market scenario among Incubator players will help the industry aspirants in planning their strategies.

Market segment by Type, the product can be split intoCarbon Dioxide IncubatorBiochemical IncubatorElectrothermal Incubator DirectlyConstant Temperature and Humidity Incubator

Market segment by Application, split intoCarbon Dioxide IncubatorBiochemical IncubatorElectrothermal Incubator DirectlyHumidity Incubator

Product Description:

In biology, an incubator is a device used to grow and maintain microbiological cultures or cell cultures. The incubator maintains optimal temperature, humidity and other conditions such as the carbon dioxide (CO2) and oxygen content of the atmosphere inside. Incubators are essential for a lot of experimental work in cell biology, microbiology and molecular biology and are used to culture both bacterial as well as eukaryotic cells.

Incubator product demand market there is also a certain space, but basically showing the scarcity of high-end products, there is a large market demand for high-end products to seize market share of imports acts.

Despite the presence of competition problems, due to the global recovery trend is clear, investors are still optimistic about this area; the future will still have more new investment enter the field.

Overview:

The growth factors of the Incubator Market are deeply discussed while the different end users of the market are underlined with the help of tables and graphs.

Further in the Incubator Market research reports, following points are included along with in-depth study of each point:-

Production Analysis Production of the Incubator is analyzed with respect to different regions, types and applications. Here, price analysis of various Incubator Market key players is also covered.

Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the Incubator Market. Also, there is a major aspect such as value, which plays an important role in the revenue generation. It is also assessed in this section for the various regions.

Supply and Consumption In continuation with sales, this section also studies the supply and consumption for the Incubator Market. This part also sheds light on the gap between supple and consumption.

Competitors In this section, various Incubator Market leading players are studied with respect to their company profile, product portfolio, capacity, price, cost and revenue.

More analysis Apart from the aforementioned information, trade and distribution analysis for the Incubator Market, contact information of major manufacturers, suppliers and key consumers is also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Available discount (Flat 30%)@:

http://www.qymarketresearchstore.com/reports/57443/discount/?Mode=86

Major Points Covered in Table of Contents:

1 Global Incubator Market Overview

2 Global Incubator Market Competitions by Manufacturers

3 Global Incubator Capacities, Production, Revenue (Value) by Region

4 Global Incubator Supply (Production), Consumption, Export, Import by Region

5 Global Incubator Productions, Revenue (Value), Price Trend by Type

6 Global Incubator Market Analyses by Application

7 Global Incubator Manufacturers Profiles/Analysis

8 Incubator Manufacturing Cost Analysis

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

10 Marketing Strategy Analyses, Distributors/Traders

11 Market Effect Factors Analysis

12 Global Incubator Market Forecast

13 Research Findings and Conclusion

14 Appendixes

Order a copy of Global Incubator Market Report 2019 @

http://qymarketresearchstore.com/reports/57443/global-incubator-market-insights-forecast-to-2025?Mode=86

Contact Us:

Irfan Tamboli (Sales)

Phone: + 1704 266 3234

[emailprotected]

Link:
Incubator Market Growth, Analysis and Advancement Outlook - Testifyandrecap